On November 2, 2023 Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, reported that new data will be presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting from December 9-12 in San Diego, CA (Press release, Orca Bio, NOV 2, 2023, View Source;utm_medium=rss&utm_campaign=orca-bio-to-present-positive-clinical-data-on-its-novel-high-precision-cell-therapies-at-the-65th-american-society-of-hematology-annual-meeting [SID1234636782]). Specifically, an oral presentation will highlight the outcomes of myeloablative Orca-T, Orca Bio’s lead investigational high-precision cell therapy, in patients over the age of 55. A second oral presentation will share updated results in an expanded group of patients with haploidentical donors treated with Orca Bio’s second investigational high-precision cell therapy, Orca-Q.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Orca Bio will also present two posters highlighting the results of patients with high-risk myelodysplastic syndrome who were treated with Orca-T, and the outcomes of patients treated with Orca-T who received reduced intensity conditioning.
The ASH (Free ASH Whitepaper) abstracts are now available at www.hematology.org. Details of the Orca Bio presentations follow:
Oral Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia
Title: Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies
Abstract Number: 230
Date and Time: Saturday, December 9, 2023 at 2:15 PM PT
Location: Marriott Marquis, Marriott Grand Ballroom 5-6
Oral Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas
Title: Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies Without the Use of Post-Transplant Cyclophosphamide
Abstract Number: 773
Date and Time: Monday, December 11, 2023 at 11:30 AM PT
Location: San Diego Convention Center, Room 6CF
Poster Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies
Title: High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T
Abstract Number: 2230
Date and Time: Saturday, December 9, 2023 at 5:30 PM PT
Location: San Diego Convention Center, Halls G-H
Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Title: Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus
Abstract Number: 3560
Date and Time: Sunday, December 10, 2023 at 6:00 PM PT
Location: San Diego Convention Center, Halls G-H
About Orca-T
Orca-T is an investigational high-precision allogeneic cell therapy for the treatment of multiple hematological malignancies. Orca-T includes infusions containing regulatory T-cells, CD34+ stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors. Orca-T is currently being evaluated in a pivotal Phase 3 clinical trial at leading transplant centers across the U.S. and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.
About Orca-Q
Orca-Q is an investigational high-precision allogeneic cell therapy designed to treat hematological malignancies in patients with haploidentical donors. Orca-Q is a proprietary composition of stem cells combined with specific T-cell subsets derived from healthy donors and engineered by Orca Bio’s high-precision platform. Orca-Q has the potential to improve patient outcomes and reduce the risks of toxicities without the use of post-transplant cyclophosphamide (PTCy) in patients unable to identify a full human leukocyte antigen (HLA) match.